Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Filings indexed 456 across all filing types
Latest filing 2023-03-24 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2023-03-24 English
PRIMARY DOCUMENT
Director's Dealing
2023-03-24 English
PRIMARY DOCUMENT
Director's Dealing
2023-03-22 English
PRIMARY DOCUMENT
Director's Dealing
2023-03-20 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2023, reporting changes in the company's board of directors and audit committee membership. It details the resignation of a director, the election of a new director, and the appointment of a new audit committee member. There is no financial data or report content, only management and board changes. This fits the category of Board/Management Information (MANG). The document length is 4795 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the classification is MANG with high confidence.
2023-03-17 English
PRIMARY DOCUMENT
Director's Dealing
2023-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.